 |
John R. Ohlfest, Ph.D.
Assistant Professor
Departments of Pediatrics and Neurosurgery
University of Minnesota, 2004, Ph.D.
ohlfe001@umn.edu
612-626-2491 - office
612-624-1195 - lab
|
Research Interests:
Cancer Immunotherapy
The Ohlfest lab is focused on understanding the mechanisms
of brain tumorogenesis and immune evasion, and translating
these basic discoveries into improved gene therapy and immunotherapy.
There are currently four projects being aggressively pursued.
* Toll-like receptor agonists as vaccine adjuvants
* Characterizing the phenotype of glioma stem cells using
in vitro and in vivo models
* Nonviral and adenoviral vector targeting to tumor cells,
employing immuno-gene therapy
* Transgenic and somatic cell gene transfer-based glioma models
Selected Recent Publications:
- Xiong Z, Gharagozlou S, Vengco I, Chen W and Ohlfest JR.
2008. Effective CpG Immunotherapy of Breast Carcinoma Prevents
but Fails to Eradicate Established Brain Metastasis. 2007
Clinical Cancer Research (in press).
- Wu A, Oh S, Ericson K, Chen L, Hall WA, Champoux PE, Low
WC, and Ohlfest JR. 2008. Persistence of CD133+ Cells in
Human and Mouse Glioma Cell Lines: detailed characterization
of GL261 glioma cells with cancer stem cell-like properties.
Stem
Cells and Development. Feb;17(1):173-84.
- Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Chen W,
Low WC, and Ohlfest JR. 2007. In Vivo Vaccination with Tumor
Cell Lysate plus CpG Oligodeoxynucleotides Eradicates Murine
Glioblastoma. Journal
of Immunotherapy.30:789-797.
- Wu A, Oh S, Ericson K, Demorest ZL, Vengco I, Gharagozlou
S, Chen W,Low WC, and Ohlfest JR. 2007. Transposon-based
Interferon Gamma Gene Transfer Overcomes Limitations of
Episomal Plasmid for Immunogene Therapy of Glioblastoma.
Cancer
Gene Therapy. 14: 550-560.
- Oh S., G. Pluhar E.G., McNeil, E.A., Kroeger, K.M., Liu
C., Castro M.G., Lowenstein P.R., Freese A., and Ohlfest,
J.R.. 2007. Efficacy of Nonviral Gene Transfer into the
Canine Brain. Journal
of Neurosurgery107:136-144.
- Wu A., Xiao J., Chen W., Hall W.A., Low W.C., and Ohlfest
J.R. 2007. Expression of MHC I and NK ligands on human CD133+
brain tumor cells: possible targets of immunotherapy. Journal
of Neuro-oncology. 83(2): 121-31.
- Ohlfest, J.R., Freese, A.B., and Largaespada, D.A. Nonviral
Vectors for Cancer Gene Therapy: Prospects for Integrating
Vectors and Combination Therapies. Current
Gene Therapy. 2005; Vol 5, No. 6, December.
- Ohlfest J.R., Demorest, Z.L., Mootoka, Y., Vengco, I.,
Oh, S., Chen, E., Scappaticci, F.A., Saplis, R.J., Ekker,
S.E., Low, W.C., Freese, A.B., and Largaespada, D.A. 2005.
Combinatorial antiangiogenic gene therapy by nonviral gene
transfer using the sleeping beauty transposon causes tumor
regression and improves survival in mice bearing intracranial
human glioblastoma. Mol
Ther. 12:778-788.
- Ohlfest, J. R., Frandsen, J. L., Fritz, S., Lobitz, P.
D., Perkinson, S. G., Clark, K. J., Nelsestuen, G., Key,
N. S., McIvor, R. S., Hackett, P. B., and Largaespada, D.
A. 2005. Phenotypic correction and long-term expression
of factor VIII in hemophilic mice by immunotolerization
and nonviral gene transfer using the Sleeping Beauty transposon
system. Blood.
April 105(7):2691-8.
- Ohlfest, J.R., P.D. Lobitz, S.G. Perkinson and D.A. Largaespada
2004. Integration and long-term expression in xenografted
human glioblastoma cells using a plasmid-based transposon
system. Mol
Ther. 10: 260-268.
Last modified on: February 28, 2008 |